These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 21504795)
1. Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease. Lamar M; Foy CML; Beacher F; Daly E; Poppe M; Archer N; Prasher V; Murphy KC; Morris RG; Simmons A; Lovestone S; Murphy DGM Neuroimage; 2011 Jul; 57(1):63-68. PubMed ID: 21504795 [TBL] [Abstract][Full Text] [Related]
2. (1)H-MRS metabolites in adults with Down syndrome: Effects of dementia. Lin AL; Powell D; Caban-Holt A; Jicha G; Robertson W; Gold BT; Davis R; Abner E; Wilcock DM; Schmitt FA; Head E Neuroimage Clin; 2016; 11():728-735. PubMed ID: 27330972 [TBL] [Abstract][Full Text] [Related]
3. Role of increased cerebral myo-inositol in the dementia of Down syndrome. Shonk T; Ross BD Magn Reson Med; 1995 Jun; 33(6):858-61. PubMed ID: 7651126 [TBL] [Abstract][Full Text] [Related]
4. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease. Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758 [TBL] [Abstract][Full Text] [Related]
5. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Ackl N; Ising M; Schreiber YA; Atiya M; Sonntag A; Auer DP Neurosci Lett; 2005 Aug 12-19; 384(1-2):23-8. PubMed ID: 15905028 [TBL] [Abstract][Full Text] [Related]
6. Hippocampal myo-inositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study. Beacher F; Simmons A; Daly E; Prasher V; Adams C; Margallo-Lana ML; Morris R; Lovestone S; Murphy K; Murphy DG Arch Gen Psychiatry; 2005 Dec; 62(12):1360-5. PubMed ID: 16330724 [TBL] [Abstract][Full Text] [Related]
7. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study. Huang W; Alexander GE; Daly EM; Shetty HU; Krasuski JS; Rapoport SI; Schapiro MB Am J Psychiatry; 1999 Dec; 156(12):1879-86. PubMed ID: 10588400 [TBL] [Abstract][Full Text] [Related]
8. Association of 1H-MR spectroscopy and cerebrospinal fluid biomarkers in Alzheimer's disease: diverging behavior at three different brain regions. Bittner DM; Heinze HJ; Kaufmann J J Alzheimers Dis; 2013; 36(1):155-63. PubMed ID: 23579327 [TBL] [Abstract][Full Text] [Related]
9. Neurometabolite mapping highlights elevated myo-inositol profiles within the developing brain in down syndrome. Patkee PA; Baburamani AA; Long KR; Dimitrova R; Ciarrusta J; Allsop J; Hughes E; Kangas J; McAlonan GM; Rutherford MA; De Vita E Neurobiol Dis; 2021 Jun; 153():105316. PubMed ID: 33711492 [TBL] [Abstract][Full Text] [Related]
10. Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment. Foy CM; Daly EM; Glover A; O'Gorman R; Simmons A; Murphy DG; Lovestone S Brain Topogr; 2011 Oct; 24(3-4):316-22. PubMed ID: 21298332 [TBL] [Abstract][Full Text] [Related]
11. The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study. Waldman AD; Rai GS Neuroradiology; 2003 Aug; 45(8):507-12. PubMed ID: 12879326 [TBL] [Abstract][Full Text] [Related]
12. Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Huang W; Alexander GE; Chang L; Shetty HU; Krasuski JS; Rapoport SI; Schapiro MB Neurology; 2001 Aug; 57(4):626-32. PubMed ID: 11524470 [TBL] [Abstract][Full Text] [Related]
13. Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice. Waragai M; Hata S; Suzuki T; Ishii R; Fujii C; Tokuda T; Arai H; Ohrui T; Higuchi S; Yoshida M; Igarashi K; Moriya M; Iwai N; Uemura K J Alzheimers Dis; 2014; 41(4):1207-22. PubMed ID: 24787913 [TBL] [Abstract][Full Text] [Related]
14. [Alzheimer's disease and magnetic resonance spectroscopy of the hippocampus]. Engelhardt E; Moreira DM; Laks J; Marinho VM; Rozenthal M; Oliveira AC Arq Neuropsiquiatr; 2001 Dec; 59(4):865-70. PubMed ID: 11733829 [TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. García Santos JM; Gavrila D; Antúnez C; Tormo MJ; Salmerón D; Carles R; Jiménez Veiga J; Parrilla G; Torres del Río S; Fortuna L; Navarro C Dement Geriatr Cogn Disord; 2008; 26(1):15-25. PubMed ID: 18566544 [TBL] [Abstract][Full Text] [Related]
16. Using proton magnetic resonance spectroscopy to identify mild cognitive impairment. Wang T; Xiao S; Li X; Ding B; Ling H; Chen K; Fang Y Int Psychogeriatr; 2012 Jan; 24(1):19-27. PubMed ID: 21676281 [TBL] [Abstract][Full Text] [Related]
17. Whole-brain patterns of (1)H-magnetic resonance spectroscopy imaging in Alzheimer's disease and dementia with Lewy bodies. Su L; Blamire AM; Watson R; He J; Hayes L; O'Brien JT Transl Psychiatry; 2016 Aug; 6(8):e877. PubMed ID: 27576166 [TBL] [Abstract][Full Text] [Related]